We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

Fintel reports that on January 22, 2025, Jefferies upgraded their outlook for Crinetics Pharmaceuticals (NasdaqGS:CRNX) from ...

We recently published a list of Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks. In this article, we are going to ...

Jefferies has upgraded Crinetics (CRNX) to buy, citing a recent pullback in the stock on investor concerns about Phase 2 data for the company's drug atumelnant. Read more here.

Jefferies analyst Dennis Ding upgraded Crinetics (CRNX) to Buy from Hold with an unchanged price target of $55. The firm cites the pullback in ...

GET MORE AI-GENERATED SIGNALS: January 08, 2025, 09:36 am ET, BY Simon M.- Contributor| Editor: Thomas H. Kee Jr. ( Follow on ...

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Crinetics Pharmaceuticals (CRNX – Research Report), ...

Crinetics Pharmaceuticals Inc (CRNX) stock saw a decline, ending the day at $40.59 which represents a decrease of $-7.91 or -16.31% from the prior close of $48.5. The stock opened at $46.64 and ...

Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at HC ...

In this article, we are going to take a look at where Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) stands against other biotech stocks with the biggest upside potential. While 2024 was a ...

Shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) traded sharply lower after the company posted initial data from a Phase 2 trial for atumelnant, its experimental therapy for congenital adrenal ...